Merck & Co. (MRK)
(Delayed Data from NYSE)
$79.29 USD
+1.17 (1.50%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $79.36 +0.07 (0.09%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MRK 79.29 +1.17(1.50%)
Will MRK be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MRK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRK
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
Stock Market News for Aug 1, 2025
MRK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?
Will Collaboration With Bain Capital Help BMY Advance Its Pipeline?
Merck Q2 Earnings Top, Sales Meet Estimates, 2025 View Narrowed
Other News for MRK
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8.5% (August 2025)
Market Voices: Trump vs. Big Pharma, Swiss tariffs, tariff legality
Trump Trade: Trump signs executive order raising tariff on Canada to 35%
Top 10 High-Yield Dividend Stocks For August 2025
European pharmaceutical stocks slip after Trump pushes for lower drug prices